The polyphosphate/factor-XII pathway in cancer-driven thrombosis and tumor growth

Project Information

PolyP-FXII in cancer

Grant agreement ID: 708495

DOI 10.3030/708495

Project terminated on 18 February 2017

EC signature date 21 March 2016

Start date 1 January 2017

End date 31 December 2018

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 159 460,80

EU contribution € 159 460,80

Coordinated by

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany

Objective

Cancer is a leading cause of venous thrombosis. Tumor-driven procoagulant mechanisms and therapies for interference with cancer-associated thrombosis are poorly developed and are associated with life-threatening bleeding complications. Coagulation factor XII is a protease that is essential for thrombus formation while being dispensable for hemostatic processes that terminate blood loss. Challenging the dogma of a coagulation balance, targeting factor XII protects from thromboembolic disease without interfering with hemostasis. The inorganic polymer polyphosphate activates factor XII with implications for thrombosis. In addition to their roles in coagulation, polyphosphate and factor XII have mitogenic activities and contribute to cell proliferation. I have recently characterized the mechanisms of polyphosphate-driven coagulation and discovered a critical function of polyphosphate/factor XII in prostate cancer-driven thrombosis. The current investigations will explore functions and mechanisms of polyphosphate/factor XII for cancer-driven coagulation and tumor growth using cancer cells in culture, genetically altered murine models and cancer patient materials. I aim to understand activation, regulation and functions of the polyphosphate/factor XII-pathway for venous thromboembolic disease as well as tumor growth. In a translational approach, I will analyze novel polyphosphate/factor XII-inhibitors for interference with cancer-driven thrombosis and tumor proliferation. The applied project will give a comprehensive insight into the function of polyphosphate/factor XII in malignancy and will offer a novel and unique opportunity for a safe anticoagulation therapy with minimal or no bleeding risk with additional anti-cancer activities.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• medical and health sciences › clinical medicine › angiology › vascular diseases
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › clinical medicine › oncology

You need to log in or register to use this function

Keywords

• Vascular biology
• Blood coagulation
• Thrombosis
• Plasma contact system
• Factor XII
• Polyphosphate
• Cancer

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2015-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF)

Call for proposal

H2020-MSCA-IF-2015

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Coordinator

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

• Net EU contribution: € 159 460,80
• Address: Martinistrasse 52 ; 20251 Hamburg ; Germany
• Region: Hamburg › Hamburg › Hamburg
• Activity type: Higher or Secondary Education Establishments
• Total cost: € 159 460,80